PROGRESS-AD Efficacy and safety of GSK4527226 in participants with early Alzheimer's disease Sponsor GlaxoSmithKline Clinical Trial Phase II Status Ongoing studies but not recruiting Drug GSK4527226
Alzheimer Sverige cost-free dementia helpline On the www.alzheimersverige.se website anyone interested (professional or private) is encouraged to call the cost-free telephone number: https://www.alzheimersverige.se/stod-radgivning/telefonradgivning/ where it is possible to speak in Farsi, Serbian, Croatian, Swedish, English and Danish. The information about the helpline is in Swedish but there... Target Audience Professional Carers People with Dementia Informal Carers General Public Communities Serbian Farsi English Danish Croatian BAME/BME Available languages Serbian Farsi English Danish Croatian Initiative Type Website Service, Support or Care
ASPIRE-FTD A study to evaluate the safety and effect of AVB-101, a gene therapy product, in subjects with a genetic sub-type of frontotemporal dementia Frontotemporal dementia Sponsor AviadoBio Ltd Clinical Trial Phase II Status Currently recruiting Drug AVB-101
AUTONOMY A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Janssen Research & Development Clinical Trial Phase II Status Ongoing studies but not recruiting Drug JNJ-63733657
CELIA A randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of BIIB080 in subjects with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Biogen Clinical Trial Phase II Status Ongoing studies but not recruiting Drug BIIB080
Clarity AD A study to confirm safety and efficacy of BAN2401 in participants with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Eisai Clinical Trial Phase III Status Ongoing studies but not recruiting Drug BAN2401
evoke evoke - A research study investigating Semaglutide in people with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Novo Nordisk A/S Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Semaglutide
evoke+ evoke+ - A research study investigating Semaglutide in people with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Novo Nordisk A/S Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Semaglutide
INFRONT-3 A Phase 3 study to evaluate efficacy and safety of AL001 in frontotemporal dementia Frontotemporal dementia Sponsor Alector Inc. Clinical Trial Phase III Status Ongoing studies but not recruiting Drug AL001
MET-FINGER METformin and FINGER intervention to prevent cognitive impairment and disability in older adults at risk for dementia At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Sponsor Imperial College London Clinical Trial Phase II Status Currently recruiting Drug FINGER 2.0 multidomain intervention
Reτain A Study of JNJ-64042056 in participants with preclinical Alzheimer's disease At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Sponsor Janssen Pharmaceutica N.V., Belgium Clinical Trial Phase II Status Currently recruiting Drug JNJ-64042056
Semaglutide A clinical study investigating the effect of semaglutide on the immune system and other biological processes in people with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Novo Nordisk A/S Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Semaglutide
TargetTau-1 Study to evaluate the efficacy, safety, and tolerability of an anti-MTBR Tau monoclonal antibody (BMS-986446) in participants with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Bristol-Myers Squibb Clinical Trial Phase II Status Ongoing studies but not recruiting Drug BMS-986446
